W.GilkisonC.JiangJ.AchacosaA.et al
semaglutide , liraglutide , dulaglutide , tirzepatide , etc.) require meticulous documentation of medical necessity, weight/BMI criteria, prior treatment failures, and demonstrated benefit, triggering detailed prior authorization (PA) requirements
Simultaneously, the neurons of the activated PVN in the hypothalamus secrete corticotropin-releasing hormone (CRH), which is transported through the hypophyseal portal system where it stimulates the anterior pituitary gland to release adrenocorticotropic hormone (ACTH) into the blood stream
Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease
Financial considerations: GLP-1s can be expensive, and insurance coverage isnt always reliable
I don't I haven't I didn't dig in with him on that, but they would have to, right